Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.1% gain over the past four weeks.The stock rallied after the company announced that its partner Biogen had made an unsolicited, non-binding proposal offer to acquire SAGE shares that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Ther ...

Sage Therapeutics, Inc. (SAGE) closed the last trading session at $6.14, gaining 9.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.72 indicates a 42% upside potential.The average comprises 18 short-term price targets ranging from a low of $4 to a high of $17, with a standard deviation of $3.54. While the lowest estimate indicates a decline of 34.9% from the current price leve ...

Sage Therapeutics, Inc. (SAGE) shares rallied 12.2% in the last trading session to close at $5.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% gain over the past four weeks.The company recently announced a strategic reorganization wherein it decided to focus on the commercialization of its depression drug Zurzuvae (zuranolone), which is marketed in partnership with Biogen. Zurzuvae is the first and o ...

Sage Therapeutics’ (SAGE) phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD) failed to meet the primary endpoint.The double-blind, placebo-controlled DIMENSION study evaluated the effects of dalzanemdor in participants with CI associated with HD.Top-line data from the study showed that dalzanemdor failed to demonstrate a statistically significant difference from baseline compared to placebo on the ...

Sage Therapeutics, Inc. (SAGE) reported a loss of $1.53 per share for the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.52. The company had reported a loss of $2.81 per share (excluding the restructuring expenses) in the year-ago quarter. Revenues in the third quarter totaled $11.8 million, significantly up from $2.7 million reported in the year-ago period. The upside can be attributed to sales of new depression drug Zurzuvae (zuranolone), which is marketed in partnership wi ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Katie Plante - Manager of Investor Relations Barry E. Greene - Chief Executive Officer Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - J.P. Morgan Salveen Richter - Goldman Sachs Yasmeen Rahimi - Piper Sandler Jay Olson - Oppenheimer Ami Fadia - ...

Third Quarter 2024 Financial Results October 29, 2024 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity","goal", "mission", "vision", "potential," "target", or "continue," and other similar expressions. • Forward-looking statements in this pre ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.52. This compares to loss of $2.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.66%. A quarter ago, it was expected that this company would post a loss of $1.68 per share when it actually produced a loss of $1.70, delivering a surprise of -1.19%. Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36544 Delaware 27-4486580 (State or other ...

Exhibit 99.1 Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late ...